CVS Pharmacy Pulls Zantac From Shelves Due to Cancer Concerns
CVS Pharmacy is pulling heartburn medication Zantac, and their own generic brand, Ranitidin, after trace amounts of a known carcinogen were found by the FDA.
The FDA had recently reported that some of the pills tested contained small amounts of N-nitrosodimethylamine (NDMA) and, according to CBSNews.com, NDMA can be harmful in large amounts.
Although the amount of NDMA found in Zantac, and it's generic counterparts, was very small, CVS has decided to error on the side of caution. The same goes for Novartis, the drug making company who says it will no longer produce the generic versions of Zantac as a direct result of this discovery.
Sanofi, the company who makes the name-brand Zantac medication, released this statement Saturday:
The FDA reported that the levels of N-nitrosodimethylamine (NDMA) in ranitidine in preliminary tests barely exceed amounts found in common foods. We are working closely with the FDA and are conducting our own robust investigations to ensure we continue to meet the highest quality safety and quality standards. At Sanofi, we remain committed to being transparent with our patients and consumers and will share an update when one is available. There are currently no plans to stop distributing or manufacturing Zantac or other ranitidine products outside of Canada.
It's ultimately up to consumers at this point. CVS Pharmacy says consumers who purchased the products in question at one of their pharmacies can bring the product back from where it was purchased.
The FDA says not to panic, but switching to another over-the-counter drug while more product testing takes place may be a good idea.